"Chronic myelogenous leukemia in primary blast crisis" rather than "de novo BCR‐ABL1‐positive acute myeloid leukemia". Issue 6 (4th April 2017)

• Record Type: Journal Article
• Authors: Pastoret, Cedric; Houot, Roch
• Is Part Of: Clinical case reports. Volume 5:Issue 6(2017)
• Page Start: 757
• Page End: 760
• Publication Date: 2017-04-04
• Subjects: Basophiloblast -- BCR‐ABL1‐positive acute myeloid leukemia -- chronic myeloid leukemia; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.937
• Languages: English
• ISSNs: 2050-0904

Abstract

Key Clinical Message: Differentiating chronic myelogenous leukemia in primary blast crisis (CML‐BC) from de novo BCR‐ABL1 ‐positive acute myeloid leukemia (AML) is a diagnostic challenge with therapeutic consequences. In our case, a basophilia, the presence of the Philadelphia chromosome in all metaphases and the strict exclusion of molecular hallmarks of AML lead us to retain the diagnosis of CML‐BC rather than BCR‐ABL1+ AML. Abstract : Differentiating chronic myelogenous leukemia in primary blast crisis (CML‐BC) from de novo BCR‐ABL1 ‐positive acute myeloid leukemia (AML) is a diagnostic challenge with therapeutic consequences. In our case, a basophilia, the presence of the Philadelphia chromosome in all metaphases and the strict exclusion of molecular hallmarks of AML lead us to retain the diagnosis of CML‐BC rather than BCR‐ABL1+ AML.